For over 50 years, the Charles O. Strickler Transplant Center at the University of Virginia has been saving the lives of Virginian’s and beyond through organ transplantation. The only transplant center in the Commonwealth where any patient— adult or child—can be transplanted with any human organ: heart, lung, kidney, liver, and pancreas, including islet cells to treat type 1 diabetes. Removing barriers, ensuring multi-disciplinary care, and providing hope are what make this program unique.
We are a leading center in minimal invasive transplant surgery using advanced robotic technologies for kidney and pancreas transplantation. We excel in the field of living donation, allowing those awaiting a kidney or liver greater possibilities.
At the University of Virginia we believe in a patient-centric approach. The research we do in our laboratories advance the science of transplantation. These advances result in better outcomes for patients in need of transplantation.
Leading Medical Research
Our current research includes:
- Clinical trials in cell therapies and advanced technologies for the treatment of diabetes and other metabolic diseases
- Using genomics to develop biomarkers capable of providing earlier diagnoses for patients, which will allow treatments to be given sooner and have a greater likelihood of success. Biomarkers could also be used to create personalized immunosuppressive medicine; to monitor how well an organ is functioning after a transplant, improving long-term post-transplantation outcomes; and to develop immunologic unresponsiveness in organ transplant recipients in the absence of drugs that suppress the immune system.
- Identifying new methods to mitigate ischemia reperfusion injury (injury that occurs to an organ during the time that it is outside a body).
- Utilizing new investigational devices to preserve and pump deceased donor organs successfully in an effort to decrease the negative effects that may occur during simple static cold preservation. These devices are also being used to investigate the organ rehabilitation capability and prolong preservation time that would allow for more organs to be used with less distance restrictions.
- Using new investigational drugs to decrease the occurrence and intensity of delayed graft function in kidney transplantation.
- Using new investigational therapies to induce tolerance in organ recipients in an effort to reduce the amount of anti-rejection medications that a patient needs, or even remove them completely.
- We are pioneers in the development of biochips that allow to study human cells and tissues in vitro, reducing the need for animal experimentation.
The Best Patient Care
Our clinical work has a record of excellence. Visit “Get the Facts” on the UVa Health Transplant Services website to view our outcomes data.
UVA Transplant is constantly working to expand the number of people who could benefit from transplant surgery and improve outcomes. Whether you are a patient, referring provider, researcher, or clinician, we appreciate your interest in the Division of Transplantation of the University of Virginia.
Please contact me if you have any questions about our program.
José Oberholzer, MD, MHCM, FACS
Chief, Division of Transplantation
Director, Charles O. Strickler Transplant Center
Professor, Surgery and Biomedical Engineer